Dr. Block is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Dana-Farber Cancer Center
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-3800- Is this information wrong?
Summary
- Dr. Caroline Block is an oncologist in Boston, MA and is affiliated with Dana-Farber Cancer Institute. She received her medical degree from University of Michigan Medical School and has been in practice 32 years. She specializes in breast cancer.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1991
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1988 - 1990
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1985 - 1988
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1986 - 1987
- Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 1985 - 1986
- University of Michigan Medical SchoolClass of 1985
Certifications & Licensure
- MA State Medical License 1987 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
- Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2009 Jun 01
- Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Start of enrollment: 2010 Apr 14
- Join now to see all
Publications & Presentations
PubMed
- PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Horm...Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma, Angela DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D Miller, Yara Abdou, Elizabeth C Riley, ...> ;Journal of Clinical Oncology. 2024 Mar 21
- Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer.Ana C Garrido-Castro, Meredith M Regan, Samuel M Niman, Faina Nakhlis, Claire Remolano, Jennifer M Rosenbluth, Caroline Block, Laura E Warren, Jennifer R Bellon, Eren ...> ;NPJ Breast Cancer. 2023 Jun 2
- 2 citationsAdjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.Stefania Morganti, Brittany L Bychkovsky, Philip D Poorvu, Ana C Garrido-Castro, Anna Weiss, Caroline C Block, Ann H Partridge, Giuseppe Curigliano, Nadine M Tung, Nan...> ;The Oncologist. 2023 Jul 5
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Brigham and Women's HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: